RadNet, Inc. (NASDAQ:RDNT) Shares Bought by Navellier & Associates Inc.

Navellier & Associates Inc. raised its holdings in RadNet, Inc. (NASDAQ:RDNT) by 4.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,501 shares of the medical research company’s stock after purchasing an additional 440 shares during the period. Navellier & Associates Inc.’s holdings in RadNet were worth $664,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. KBC Group NV raised its position in shares of RadNet by 47.6% in the 4th quarter. KBC Group NV now owns 2,678 shares of the medical research company’s stock valued at $187,000 after purchasing an additional 864 shares in the last quarter. Lisanti Capital Growth LLC acquired a new stake in shares of RadNet during the 3rd quarter valued at approximately $2,922,000. Franklin Resources Inc. raised its position in shares of RadNet by 12.0% during the 3rd quarter. Franklin Resources Inc. now owns 387,061 shares of the medical research company’s stock valued at $27,334,000 after acquiring an additional 41,381 shares in the last quarter. Pathstone Holdings LLC raised its position in shares of RadNet by 58.5% during the 3rd quarter. Pathstone Holdings LLC now owns 27,503 shares of the medical research company’s stock valued at $1,908,000 after acquiring an additional 10,151 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of RadNet by 30.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,475,995 shares of the medical research company’s stock valued at $103,532,000 after acquiring an additional 344,146 shares in the last quarter. 77.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP David Jeffrey Katz sold 12,300 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $81.65, for a total transaction of $1,004,295.00. Following the completion of the transaction, the executive vice president now directly owns 62,909 shares in the company, valued at $5,136,519.85. This represents a 16.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.12% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Jefferies Financial Group dropped their price target on RadNet from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Wednesday, January 15th. Truist Financial reissued a “buy” rating and set a $88.00 price target (down from $94.00) on shares of RadNet in a research report on Wednesday, January 22nd. Finally, Barclays dropped their price target on RadNet from $85.00 to $74.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, RadNet currently has an average rating of “Moderate Buy” and a consensus target price of $75.50.

RadNet Price Performance

Shares of RDNT opened at $59.47 on Friday. The company has a market cap of $4.40 billion, a P/E ratio of -849.45 and a beta of 1.79. The stock has a fifty day moving average price of $67.00 and a 200 day moving average price of $69.14. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.16 and a quick ratio of 2.16. RadNet, Inc. has a 12 month low of $36.47 and a 12 month high of $93.65.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.